M&A in the medical devices sector: full seminar

On Wednesday 13 April I organised a seminar and realtime webinar at my firm about M&A in the medical devices sector, to discuss the legal and regulatory implications of an M&A project in the medical devices industry, what mistakes are typically made and how to prepare a medical devices company for an M&A transaction, whether it is a target or a buyer. A topical subject, now that M&A activity seems to be picking up again, for example with J&J eyeing Synthes presently.

Speakers were Hans Dulmen, CEO of Dulmen Regualtory Services, Jan van Lochem, Vice President Healthcare at BSi and myself. The full presentations of the seminar are here.

Hans van Dulmen gave a detailed account of the possible impact of an M&A project on a medical device’s quality system and about how to prepare a company, device or product line to be sold to another company with the least regulatory and organisational surprises. I think he also gave some good due diligence tips, both for seller and buyer due diligence.

Jan van Lochem addressed M&A transactions from the perspective of a notified body and emphasized a timely assessment of the impact of the acquisition on a company’s quality system and planning of the necessary assessment of the changes by the company’s notified body. Poor planning can cause problems, notably if the acquired devices cannot be integrated in the acquirer’s quality system timely and may not be covered by the seller’s declaration of conformity anymore.

I myself spoke about the legal issues that may arise, such as regulatory warranties, due diligence and possible renegotiation of distributor, agent and supply contracts, what to look for in a due diligence of a medical devices company from a medical devices specialist point of view (with specific emphasis on FCPA and anti-bribery law) and transitional service agreements for handover of a device from one quality system to the other.

The general conclusion of the seminar was that the issues discussed unfortunately often do not get the attention they deserve, often leading to unnecessary and costly problems and hold-ups.

It was all well attended and well rated seminar. We are currently remastering the full webinar recording, which I will also post when the work on it is done.


Navigate through our knowledgebase

Related articles

Article

The EU Court’s Schrems II judgement – urgent revisiting of international personal data transfer mechanisms required

Wasn’t the MDR about More Data Required, and the same for the IVDR? Aren’t more and more devices running software that processes patient and user data? Isn’t the medical devices industry a…

Read more

Article

The EU Court’s Schrems II judgement – urgent revisiting of international personal data transfer mechanisms required

Wasn’t the MDR about More Data Required, and the same for the IVDR? Aren’t more and more devices running software that processes patient and user data? Isn’t the medical devices industry a very international business? Indeed – so the ability for companies working with the MDR and IVDR to transfer personal data internationally for all […]

Article

Impossible and Incredible And Yet Really Happened

What can we learn from the Impossible vs. Incredible case in the Netherlands? At the end May this year, the Court of The Hague rendered a remarkable judgment: at the request of Impossible Foods, Nestlé was banned from launching its INCREDIBLE BURGER in the EU. How is this possible? Impossible Foods is not even on […]